The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Jordan Gauthier, MD, MSc
Advertisement
Articles by Jordan Gauthier, MD, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer
2
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
3
Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer
4
FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM
5
